Latest close
$84.01
As of Oct 2, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Oakmark Funds | 2.15% | 17,329,926 | TRIMMED (-3.7%) |
| Berkshire Hathaway | 1.79% | 57,320,000 | ADDED (+44.0%) |
| Patient Capital Management | 1.32% | 431,215 | TRIMMED (-22.0%) |
| Pzena Investment Management | 0.72% | 2,618,707 | TRIMMED (-6.7%) |
| First Eagle Investment Management | 0.00% | 15,212 | ADDED (+26.3%) |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end.
| Institutions holding | 1,528 of 8,857 filers |
| Long-only filers among them | 1,515 |
| Change vs 2026 Q1 | +195 net · 1,300 entered · 1,105 exited |
| Shares reported, all filers | 578,860,895 |
| Reported value, all filers | $56.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 6 sales by 6 insiders ($33.1M).
Source: SEC Form 4 filings, as of Oct 3, 2026. Open-market transactions only.
Data unavailable — no House STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Growth — Revenue up every year for 5 straight years
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Key figures
· Buffett — Latest ROE: 24.0% · Years ROE ≥15% (of 10): 8 · 10-yr avg ROE: -57.0% · Latest net income: $5.0B
· Growth — Latest revenue: $63.4B · 5-yr revenue CAGR: 30.0% · Straight growth years: 5
· Cash Flow (FCF) — Latest FCF: $3.8B · FCF yield: 7.0% · Positive FCF years: 3
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.80 · Operating cash flow: $8.3B · Net income: $5.0B
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2021 Q3, ranked #43 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 3 | 33.3% | +6.5% | +5.0% | +1.5% |
| Share count tripled (3x) | 1 | 0.0% | -16.6% | +1.9% | -18.5% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Open this in the GetCoattail app →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.